Literature DB >> 11380817

Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.

C C Najafi1, S M Korbet, E J Lewis, M M Schwartz, M Reichlin, J Evans.   

Abstract

BACKGROUND: Patients with systemic lupus erythematosus have a spectrum of glomerular disease, but the different patterns of glomerular injury identified within the general category of "severe" lupus glomerulonephritis are responsible for much of the morbidity and mortality in this disease. The glomerular injury patterns seen with severe lupus glomerulonephritis have been separated into distinct histopathologic groups to determine whether they can predict long-term patient outcome.
METHODS: We analyzed the clinical follow-up of 85 patients participating in a controlled prospective therapeutic trial for the treatment of severe lupus glomerulonephritis conducted from April 1981 to December 1988, with an average follow-up of 10 years. Patients were classified according to the 1982 World Health Organization classification for lupus glomerulonephritis.
RESULTS: During the course of follow-up [120 +/- 65 (SD) months], 60% of patients with category IV (diffuse proliferative glomerulonephritis) lesions entered a remission compared with only 38% of patients with category III (> or =50%, focal and segmental glomerulonephritis) lesions and 27% of patients with category Vc (> or =50%) and Vd (P < 0.05). Renal survival at 10 years was 75% for those with category IV lesions, 47% for patients with category Vc (> or =50%) and Vd, and 52% for patients with category III (> or =50%) lesions (P < 0.05). Based on multivariate analysis, patients with category III (> or =50%) or Vc (> or =50%) and Vd lesions had a relative risk of progression to end-stage renal disease 2.9 times that of category IV patients (P < 0.01), while the likelihood of entering a remission was 8.2 times greater for category IV patients (P = 0.0001).
CONCLUSION: The histopathologic categorization among patients with severe lupus glomerulonephritis provides information relevant to their long-term outcome.

Entities:  

Mesh:

Year:  2001        PMID: 11380817     DOI: 10.1046/j.1523-1755.2001.00730.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  48 in total

Review 1.  Complement in the immunopathogenesis of rheumatic disease.

Authors:  Gunnar Sturfelt; Lennart Truedsson
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 2.  Treatment of severe proliferative lupus nephritis: the current state.

Authors:  C C Mok; R W S Wong; K N Lai
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

3.  Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes.

Authors:  Catharina M Haring; Anke Rietveld; Jan A J G van den Brand; Jo H M Berden
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

4.  Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.

Authors:  Takayuki Katsuno; Takenori Ozaki; Takaya Ozeki; Asaka Hachiya; Hangsoo Kim; Noritoshi Kato; Takuji Ishimoto; Sawako Kato; Tomoki Kosugi; Naotake Tsuboi; Masashi Mizuno; Yasuhiko Ito; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2018-05-23       Impact factor: 2.801

Review 5.  The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.

Authors:  Suzanne Wilhelmus; Charles E Alpers; H Terence Cook; Franco Ferrario; Agnes B Fogo; Mark Haas; Kensuke Joh; Laure-Hélène Noël; Surya V Seshan; Jan A Bruijn; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

Review 6.  [What rheumatologists can learn from nephrologists].

Authors:  V Schwenger
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

7.  Pauci-immune and immune glomerular lesions in kidney transplants for systemic lupus erythematosus.

Authors:  Shane M Meehan; Anthony Chang; Amandeep Khurana; Rajendra Baliga; Pradeep V Kadambi; Basit Javaid
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 8.237

Review 8.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

9.  Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity.

Authors:  Samih H Nasr; Vivette D D'Agati; Hye-Ran Park; Paul L Sterman; Juan D Goyzueta; Robert M Dressler; Shawn M Hazlett; Robert N Pursell; Christopher Caputo; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

Review 10.  Usefulness of ISN/RPS classification of lupus nephritis.

Authors:  Ken-Ei Sada; Hirofumi Makino
Journal:  J Korean Med Sci       Date:  2009-01-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.